Updated efficacy and safety results from a phase II single-arm trial (SGN35-027) evaluating the antibody-drug conjugate Adcetris (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine for the frontline treatment of patients with early-stage classical Hodgkin lymphoma showed a 98% overall response rate and a 93% complete response rate at the end of treatment.
Krish Patel was appointed director of lymphoma research at Sarah Cannon Research Institute.
